NeurogesX Reports Second Quarter 20...(a is currently approved in the European ...)

Date:8/7/2009

a is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the design and timing of further development efforts.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; acceptance of clinical trial or other data, analysis or informati
'/>"/>

SOURCE NeurogesX, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
2. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
3. NeurogesX Added to Russell 3000 Index
4. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
5. NeurogesX to Present at Needham Life Sciences Conference
6. NeurogesX Receives European Commission Approval for Qutenza(TM)
7. NeurogesX Reports First Quarter 2009 Results
8. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
9. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
10. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
11. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union